Headquartered in San Diego, CA Fiscal year ends December NASDAQ: NBIX neurocrine.com
Neurocrine Biosciences is a biopharmaceutical company focused on discovering, developing, and commercializing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. The company's commercial portfolio includes three FDA-approved products: INGREZZA (valbenazine) for tardive dyskinesia and chorea associated with Huntington's disease; CRENESSITY (crinecerfont) for classic congenital adrenal hyperplasia; and VYKAT XR (diazoxide choline), acquired through the May 2026 purchase of Soleno Therapeutics, for hyperphagia in Prader-Willi syndrome. Neurocrine also has collaborative partnerships with AbbVie for endometriosis and uterine fibroids treatments. The company's pipeline includes multiple mid- to late-phase clinical programs, notably osavampator (Phase 3 for major depressive disorder) and direclidine (Phase 3 for schizophrenia), both with readouts expected in 2027. The company trades on Nasdaq under the ticker NBIX. Updated
Pre-Market Stock Futures: Futures are trading higher after we started off the first full trading week of the 4th quarter in solid style, as all major indices finished the day higher despite…
Crinetics Pharmaceuticals (NASDAQ:CRNX) shares have climbed 99% just this week, from $42.03 at Monday’s close, to $83.54 earlier today. The simple reason: Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) agreed to acquire…
Pre-Market Stock Futures: Futures are trading higher this morning after a dreadful day to start the trading week. Various reasons were cited for the risk-off bias on Monday, but the tariff situation,…
Pre-Market Stock Futures: The futures are trading lower on Thursday after investors and traders tapped the brakes on the 2026 new year rally, as only the Nasdaq was able to grind out…
Neurocrine Biosciences (NASDAQ: NBIX | NBIX Price Prediction) delivered a decisive earnings beat in Q3, posting adjusted EPS of $2.17 against expectations of $1.62 and revenue of $794.9M versus $761.4M consensus. The…
Joel South If you work in the biotech industry, you might know the name Alex Denner. If not, his name probably doesn’t ring a bell. Denner is the CEO and CIO of Sarissa Capital…
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
Thursday's top analyst upgrades and downgrades included Best Buy, Carnival, Caterpillar, Centene, ChargePoint, Foot Locker, Hewlett Packard Enterprise, Palo Alto Networks, PDD, Peloton Interactive, Realty Income, Sunrun, Texas Instruments and UDR.
Thursday's top analyst upgrades and downgrades included Advanced Micro Devices, Caesars Entertainment, Caterpillar, CrowdStrike, Crown Castle, Electronic Arts, Estee Lauder, KeyCorp, Match, Norwegian Cruise Line, Sirius XM, SoFi Technologies and TG Therapeutics.
Tuesday's top analyst upgrades and downgrades included American Express, Apple, AppLovin, Conagra Brands, D.R. Horton, Estee Lauder, Juniper Networks, Livent, Microsoft, Netflix, Nvidia, Shopify, Tesla, and Twilio.
Friday's top analyst upgrades and downgrades included American Express, Aptiv, BorgWarner, First Horizon, Keurig Dr Pepper, Meta Platforms, MGIC Investment, Simon Property Group and Teva Pharmaceutical Industries.
Friday's top analyst upgrades and downgrades included Builders FirstSource, CVS Health, DHT, Incyte, McDonald's, Newell Brands, PacWest Bancorp, Wingstop and ZoomInfo Technologies.
Wednesday's top analyst upgrades and downgrades included Annaly Capital Management, Capri, Chegg, Coinbase Global, CrowdStrike, Dell Technologies, Fortinet, HP, Kohl's, Palo Alto Networks, Penn Entertainment, Shoals Technologies, SoFi Technologies and ZScaler.
Friday's top analyst upgrades and downgrades included American Tower, Charles Schwab, Crown Castle, DiamondRock Hospitality, DraftKings, Enphase Energy, GitLab, Interpublic Group of Companies, Juniper Networks, Philip Morris International, Shoals Technologies and Sunrun.
Monday's top analyst upgrades and downgrades included Bill.com, Boeing, Cardinal Health, Cognizant Technology Solutions, ConocoPhillips, C3.ai, Enphase Energy, Ford, International Paper, Meta Platforms, Nordstrom, Spirit Aerosystems and Upstart.
Neurocrine Biosciences is a biopharmaceutical company focused on discovering, developing, and commercializing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders.
24/7 Wall St.'s 12-month price target for NBIX is $184.97, rated Buy. The Wall Street consensus target is $206.81. NBIX price prediction →
